key: cord-0711154-9rvzkcqm authors: Giuliani, Federica; Gualdi, Giulio; Amerio, Paolo title: Effect of immunosuppressive drugs in Immune‐mediated Inflammatory disease during the Coronavirus pandemic date: 2020-08-23 journal: Dermatol Ther DOI: 10.1111/dth.14204 sha: e45e147ebd3fb28305844ab667c5860ae57d6749 doc_id: 711154 cord_uid: 9rvzkcqm The safety of immunosuppressive treatment in patients with Immune‐Mediated Inflammatory Diseases (IMIDs) during the Coronavirus pandemic is questioned and it is utmost important for public health. We searched studies trough MEDLINE/EMBASE database, including patient with IMID, undergoing immunosuppressive treatment with a positive diagnosis for SARS‐CoV 2. We included 11 studies for the descriptive analysis and 10 studies for the pooled analysis, with a total population of 57 and 53 IMID‐affected SARS‐CoV‐positive patients respectively. Overall no death was reported; 16 patients were hospitalized (30.2%) and only 2 cases were admitted to Intensive Care Unit (ICU) (3.8%). We found a significant association between the risk of hospitalization and older age (p 0.03), obesity (p 0.02) and presence of multi‐comorbidity (p 0.03). No significant association was found between the risk of hospitalization and the use of biological or conventional DMARDs (respectively p 0.32 and 0.26), neither when they are used combined (p 0.85). We found consistent results in the sub‐analysis of Psoriasis: 10 patients were hospitalized (31.3%) and only 1 case was admitted to Intensive Care Unit (ICU) (3.1%) Particular attention should be placed for patients with older age, obesity and multi‐comorbidity that are at higher risk of hospitalization. This article is protected by copyright. All rights reserved. Whether patients under biological treatment for dermatologic, rheumatologic or gastroenterological immune mediated diseases (IMIDs) should stop or continue therapy during Coronavirus pandemic has been a matter of debate (1) . It has been advised that since the rate of respiratory infection during clinical trials with biologics for psoriasis was comparable with placebo and that these drugs should not be withhold (1) . In IBD patients, although, figures suggest that infection rate is low (2) , fear of a worst outcome in immunosuppressed patients has been put forward (3) . Remarkably, in several IMID not undergoing immunosuppressive treatment was detected latent airway inflammation with the technique of fraction exhaled nitric oxide (FeNO) that may contribute to increase COVID-19 vulnerability synergically with the dysimmunity typical of IMID (4) (5) (6) (7) . The use of some biological drug has been even suggested to ease the severity of lung disease following the infection (8, 9) . Pooled data on the clinical fate of SARS-CoV2 infected patients under biologicals were not available in literature to have any clue on this new pandemic. Data on the outcome of the same type of patients from first coronavirus pandemic with SARSCoV1 may help to understand how to manage these cases in the current pandemic. For this reason we performed a systematic review on patients with IMIDs treated with biologics or conventional DMARDs that become infected with SARS-CoV2 or SARS-CoV1 and analyzed their clinical outcome. We searched studies from the database PubMed MEDLINE and OVID Embase, using the strategy shown in Table 1 . Two physicians independently (FG and GG) proceeded to abstracts screening, according to inclusion and exclusion criteria, examined full-text articles to determine eligibility and discussed disagreements to reach consensus. We listed excluded studies and primary reasons for exclusion ( Figure 1 ), then we extracted data from reports. We also check the references of the included studies. We included case report, case series, letter, review, register, prospective and retrospective studies, in English language and Human. We excluded conference abstract. We considered the outcomes "hospitalization", "admission in Intensive Care Unit" and "death". We included adult and paediatric patients with a confirm diagnosis of Coronavirus infection made by naso/oro-pharyngeal swab for RT-PCR, affected by dermatologic, rheumatologic and gastroenterological IMID, undergoing immunosuppressive therapy, including biologic and conventional DMARDs (as listed in table 1). We excluded type of Psoriasis other than plaque psoriasis and psoriatic arthritis. This article is protected by copyright. All rights reserved. Individual patient data were pooled from 10 reports (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Categorical variables are described as absolute frequencies and percentages and continuous variables are presented as mean values ± standard deviation (SD). Fisher and t-test were used to compare variables between subjects with or without hospitalization. A two-sided P value <0.05 was considered statistically significant. Statistical analyses were performed by SPSS version 20.0 (IBM Inc., IL, USA). We excluded the unique study (20) that contributed with one patient affected by SARS-CoV 1 infection, to avoid selection bias. We excluded 4 patients from three reports (14, 15, 17) for the comorbidity descriptive and pooled analysis because of unclear/missing data. The study by Monti et al. (21) included only mean values of the 4 patients included, without individual data, and was thus accordingly excluded in the pooled analysis. We identified through database searching 300 records: 6 have been excluded because duplicates or conference abstract; 294 records have been screened for titles and abstracts; then we excluded 199 records and we assessed 95 full text articles for eligibility. Of these, 83 full text articles were excluded and 12 records were included for qualitative synthesis. We extract data for a quantitative analysis of 11 complete records. For further descriptions see the study flow-diagram ( Figure 1) We included 11 reports (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) 21) for quantitative descriptive analysis, with a total population of 57 SARS-CoV 2 confirmed-infected patients, with an average age of 49.2 years (SD 17. 6) , and an equally gender distribution (29 M, 50.8%) ( Table 2) From a total population of 53 patients (see Missing data), 13 had more than one comorbidity (24.5 %). Comorbidities were: hypertension (26.4%), diabetes (9.4%), cardio-cerebrovascular disease (9.4%), obesity (11.3%) and other (26.4%). On a total population of 57 patients, 50 patients were treated with a biologic therapy (87.7%) and 1 patient with a JAK inhibitor (Tofacicitinib, 1.7%). Six patients used conventional DMARDs alone (10,5%) and ten patients were treated with combined biologic and conventional DMARDs (17.5%). (see Table2) . We conducted a pooled analysis on 10 reports 1-10 regarding 53 patients (see Missing data for population details) affected by SARS-CoV 2, with a previous diagnosis of IMIDs, treated with a This article is protected by copyright. All rights reserved. biologic and/or conventional DMARDs, with the objective to assess how the drug-induced immunosuppressive status could impact the severity of the SARS-CoV infection clinical course. We also analyse the association between demographic patients characteristic and the outcomes "hospitalization" (Table 3) No death was reported; 16 patients were hospitalized (30.2%, 95% CI 17.8-42.6%) and only 2 cases were admitted to Intensive Care Unit (ICU) (3.8%, 95% CI -1.3-8.9)(see Table 2 ). We found a significant association between the risk of hospitalization and older age (p 0.03), Table 3 ) We also conducted a pooled analysis on 7 reports regarding 32 patients affected by COVID-19, with a previous diagnosis of Psoriasis, treated with a biologic and/or conventional DMARDs, with the objective to assess how the drug-induced immunosuppressive status could impact the severity of the SARS-CoV infection clinical course. We also analyse the association between demographic patients characteristic and the outcomes "hospitalization" (Table 4) . Also in this group no death was reported; 10 patients were hospitalized (31.3%, 95% CI 15.2-47.3%) and only 1 case was admitted to Intensive Care Unit (ICU) (3.1%, 95% CI -2.9-9.2%)(see Table 1 ). We observed a significant association between the risk of hospitalization and older age (p 0.04). A positive trend for the outcome "hospitalization" was found for the variable diabetic (p 0.07). Even in the psoriatic population, no significant association was found between the risk of This article is protected by copyright. All rights reserved. hospitalization and the use of biological or conventional DMARDs (respectively p 0.55 and p 0.13), neither when they are used combined (p 0.49) (see Table 4 ). While in some individuals, the COVID-19 disease remains asymptomatic, albeit infective, other individuals present severe complications (25) . Around 15% of patients develop severe pneumonia and 5% progress to an acute respiratory distress syndrome, septic shock and/or a multiple organ failure, associated with high mortality (26) . Both innate and adaptive immune response were implicated in the severity differential of this disease (27) . A "cytokine storm" following hyper-activation of the immune system seems to be responsible for this progression (28) . Several cytokines such as IP-10, MCP-1 IL-2, IL-6, IL7, GM-CSF and TNF alpha have been related not only to the severity of the disease but also with the probability of being admitted to the ICU (29, 30) . This article is protected by copyright. All rights reserved. In particular high TNF alpha and IL-6 levels have been described as biomarkers of worse outcome in particularly fragile cancer patients infected with SARSCoV2(31). Since immunosuppression across multiple cytokine axes has the potential to increase susceptibility, persistence, and reactivation of viral infections, the question for dermatology, rheumatology and gastroenterology was whether to halt therapies for IMIDs patients during this pandemic. The discontinuation of immunosuppressants in IMIDs, however, may lead to disease flares, and severe psychological distress, that sometimes could be more harmful than stopping the therapy for the fear We focused our review on the evaluation of immunosuppressants impact during COVID-19 outbreak in the understudied IMID population. In our pooled analysis we found that 30.2% of SARS-CoV positive patients undergoing immunosuppressive or immunomodulatory therapy was hospitalized. When we analyzed the subgroup of psoriatic patients under therapy this figure remained stable at 31.3 %. In Italy the hospitalization rate in the same period taken in consideration in our study was 16,9 %(36), but a direct comparison is not methodologically correct since the cases collected in our study come from different countries and they represent a selected population, not the totality of IMIDs patients This article is protected by copyright. All rights reserved. undergoing immunosuppressive therapy. Instead as for the severity of the disease we found that 3,5 % of the patients collected in our pooled analysis was admitted to ICU and this is very similar to the rate of ICU admission recorded in the Italian COVID-19 population(36). We found that the features that may predict a worse prognosis for IMID treated patients were age, obesity and multi-comorbidity. Among the comorbidities usually described as being associated with a higher risk of infection and disease severity only diabetes and hypertension showed a tendency towards statistical significance in the patients collected. This is in line with the literature that demonstrates that, among several clinical features and comorbidities that may predict the severity of the disease and thus the admission to ICU, age was the strongest of all (37) . As for the role of therapy, although the numbers are very small, our pooled analysis showed that nor classical DMARDs neither biological previous treatment, generates a higher risk of hospitalization in IMID patients and more specifically to psoriatic patients treated with these drugs. We think that this evidence may be helpful in guiding the management of these patients. Moreover this may be in line with the hypothesis that some level of immune modulation may be worthwhile to control the complication of COVID-19 infection (38) . Although there have been no cases of patients treated with Apremilast included in our review, the evidence is in support of a good safety profile with this drug (39) and probably this is the main reason for their absence. Indeed many authors reported that none of the patients treated with Apremilast developed COVID-19 related symptoms (40) . We combined the present evidences from this paper with the management suggestion already in place(41, 42), and developed an algorithm for the management of patients treated with DMARDs This article is protected by copyright. All rights reserved. during this pandemic (Figure 2 ). The main limitation of our pooled analysis is the small sample size, possibly not allowing adequate statistical power, even if representing an insightful description of the now available best knowledge about the topic. Our systematic review and pooled analysis on COVID-19 infected IMID patients treated with immunosuppressive and immunomodulatory drugs showed that there is no difference in the hospitalization rate for DMARDs users. Particular attention should be placed for patients with older age, obesity and multi-comorbidity in treatment with these drugs. Values are expressed as mean±SD or n (%). M = male, bDMARDs = biologic disease-modifying antirheumatic drugs, cDMARDs = conventional disease-modifying antirheumatic drugs. † numbers indicates patients on bDMARDs or cDMARDs monotherapy. ‡, §, ¶ Missing data for comorbidity modify the total population analyzable (on a total population of ‡49, §13 and ¶ 36 patients). Values are expressed as mean±SD or n (%). M = male, bDMARDs = biologic disease-modifying antirheumatic drugs, cDMARDs = conventional disease-modifying antirheumatic drugs. † numbers indicates patients on bDMARDs or cDMARDs monotherapy. ‡, §, ¶ Missing data for comorbidity modify the total population analyzable (on a total Should biologics for psoriasis be interrupted in the era of COVID-19? Asian Pacific journal of cancer prevention : APJCP SECURE-IBD Database Public Data Update Are patients with inflammatory bowel disease at increased risk for Covid-19 infection? Journal of Crohn's & colitis Patients with psoriatic arthritis have higher levels of FeNO than those with only psoriasis, which may reflect a higher prevalence of a subclinical respiratory involvement Malar rash is a predictor of subclinical airway inflammation in patients with systemic lupus erythematosus: a pilot study Increased airway inflammation in patients with psoriasis. The British journal of dermatology Exhaled nitric oxide as a marker of lung involvement in Crohn's disease Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions COVID-19: a case for inhibiting IL-17? SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor. Dermatologic therapy Improvement of SARS-CoV2 symptoms following Guselkumab injection in a psoriatic patient Evolution of COVID-19 infection in 4 psoriatic patients treated with biological drugs Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: real-life data from a large cohort during RED-ZONE declaration SARS-CoV-2 infection among patients with systemic autoimmune diseases The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience. The British journal of dermatology SARS-CoV-2 infection in a psoriatic patient treated with IL-23 A challenging case of psoriasis flare-up after COVID-19 infection COVID-19 and Paediatric Inflammatory Bowel Diseases: Global Experience and Provisional Guidance Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association Lupus pneumonitis or severe acute respiratory syndrome? Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Annals of the rheumatic diseases Summary table of SARS cases by country Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. The Lancet Infectious diseases Clinical and laboratory findings of SARS in Singapore COVID-19 in the heart and the lungs: could we "Notch" the inflammatory storm? Basic research in cardiology COVID-19: immunopathology and its implications for therapy Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19 COVID-19 and the immune system COVID-19: consider cytokine storm syndromes and immunosuppression Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive care medicine Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. The Lancet Oncology COVID-19 and psoriasis : should we fear for patients treated with biologics? Psoriasis and Psoriatic Arthritis: how to manage Immunosuppressants in COVID-19 days COVID-19, syphilis, and biologic therapies for psoriasis and psoriatic arthritis: A word of caution. The Journal of dermatological treatment No advice to discontinue antirheumatic therapy for non-medical reasons in light of SARS-CoV-2. Response to: 'Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic' by Fragoulis et al. Annals of the rheumatic diseases A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: an observational cohort study. The Journal of infection Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques Rationale for Evaluating PDE4 Inhibition for Mitigating against Severe Inflammation in COVID-19 Pneumonia and Beyond Clinical efficacy, speed of improvement and safety of apremilast for the treatment of adult Psoriasis during COVID-19 pandemic This article is protected by copyright. All rights reserved.